About Rogers Corp
- Industry: Electrical Equipment
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.rogerscorp.com/
Frequently Asked Questions
What is the 52-week range for ROG?
The 52-week high is $169 and the 52-week low is $75.14.
What is the P/E ratio for ROG?
The Price to Earnings (P/E) ratio is 91.34.
What is the dividend yield for ROG?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 2.61%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 3.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.38.
Analyst Recommendation Trends
Wall Street analyst consensus for ROG over the last few months:
Latest ROG News
Rogers Targets $1.5B Sales by 2030 on AI Data Center, Battery Growth
Rogers (NYSE:ROG) outlined a plan to grow annual sales to more than $1.5 billion by 2030, supported by expansion in its core markets and targeted opportunities in AI data centers, battery systems and electromagnetic interference, or EMI, shielding. At the company’s 2026 Analyst and Investor Day, Pr
Rogers Corp. (ROG) Moves 10.7% Higher: Will This Strength Last?
Rogers Corp. (ROG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
B. Riley Securities Maintains Buy on Rogers, Raises Price Target to $225
B. Riley Securities analyst Craig Ellis maintains Rogers (NYSE:ROG) with a Buy and raises the price target from $200 to $225.
Freedom Capital Markets Maintains Buy on Rogers, Raises Price Target to $185
Freedom Capital Markets analyst David Silver maintains Rogers (NYSE:ROG) with a Buy and raises the price target from $150 to $185.
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical p
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes1The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026 Basel, 1 Oct
Rogers Corporation (ROG) Analyst/Investor Day - Slideshow
2026-10-01. The following slide deck was published by Rogers Corporation in conjunction with this event.
Rogers Corporation (ROG) Analyst/Investor Day Transcript
Rogers Corporation (ROG) Analyst/Investor Day September 30, 2026 9:00 AM EDTCompany ParticipantsStephen Haymore - Senior Director of Investor RelationsAli...
Rogers Stock Surges 11% After Investor Day. Here’s Why
Rogers Stock Jumps 11% as Investor Day Sets $1. 5 Billion 2030 Revenue TargetRogers Corporation (ROG:NYSE) stock climbed 10.
Rogers (ROG) Shares Skyrocket, What You Need To Know
Shares of engineered materials manufacturer Rogers (NYSE:ROG) jumped 17% in the morning session after it hosted an Investor Day, where management laid out strategy and multi-year financial targets through 2030. According to the company’s Investor Day presentation, President and CEO Ali El-Haj and CFO Laura Russell outlined growth priorities tied to AI data centers, vehicle electrification, and capital allocation, along with financial objectives through 2030. Management targeted about a 13% reven
Rogers Corporation Provides 2030 Financial Targets at 2026 Investor Day
CHANDLER, Ariz., September 30, 2026--Rogers Corporation (NYSE: ROG) ("Rogers") today presented its strategy to accelerate growth, expand profitability and increase earnings through 2030 at the Company’s 2026 Investor Day.
Rogers Sees FY2030 Adj EPS $14.00; Sees Sales $1.500B
Rogers (NYSE:ROG) is looking for FY2030 Adj EPS of $14.00. sees sales of $1.500 billion.
Rogers Sees FY2028 Adj EPS $5.50-$6.50; Sees Sales $1.000B-$1.100B
Rogers (NYSE:ROG) is looking for FY2028 Adj EPS of $5.50-$6.50. sees sales of $1.000 billion-$1.100 billion.
Rogers Expects FY28 Adjusted EPS Range $5.50 - $6.50, Revenue Range $1B - $1.1B, FY2030 Adjusted EPS Of $14, Revenue $1.5B
Rogers Corporation (NYSE: ROG) ("Rogers") today presented its strategy to accelerate growth, expand profitability and increase earnings through 2030 at the Company’s 2026 Investor Day.Rogers announced the
Rogers Corporation to Host Investor Day on September 30, 2026
CHANDLER, Ariz., September 30, 2026--Rogers Corporation (NYSE:ROG) ("Rogers") will host an Investor Day, Wednesday, September 30, 2026, in New York City.
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus2Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression1
3 Russell 2000 Stocks We Steer Clear Of
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Rogers (ROG) Stock Looks Overvalued After Its 73% Rise
Rogers has delivered a sharp move over the past year, which puts today’s valuation squarely in focus. With the share price well above where it started the period, the question now is how much of that climb is supported by the company’s earnings power. The stock has returned 72.6% over the past year, which raises the stakes on whether current buyers are paying a full price for its earnings profile. The business depends heavily on its ability to convert specialized materials demand into steady...
3 Small-Cap Stocks We Find Risky
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potentialSefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring
Change in Roche’s Board of Directors
Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan: “I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe’s intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic controlIn patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeksBy week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of ≤6.5% HbA1c, while 62% achieved normoglycemia (HbA1c < 5.7%)At the highest 24 mg dose, enicepatide achieved a mean weight loss
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3Susvimo helps people with nAMD maintain their vision with as few as two treatments per year1-3Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections2nAMD is a leading cause of vision loss in adults
3 Low-Volatility Stocks We Find Risky
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO, ROP;
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and developmentIt will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubsThis is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturin
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatmentData reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health auth
1 Cash-Heavy Stock with Competitive Advantages and 2 That Underwhelm
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3Roche is de
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)Filing acceptance is based on the Phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%1 MOGAD is a rare disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain2,3 Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S.
Electronic Components & Manufacturing Stocks Q2 Results: Benchmarking Rogers (NYSE:ROG)
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how electronic components & manufacturing stocks fared in Q2, starting with Rogers (NYSE:ROG).
Rogers Corporation Announces Investor Day on September 30, 2026
CHANDLER, Ariz., September 09, 2026--Rogers Corporation (NYSE:ROG) ("Rogers") today announced that it will host an Investor Day on Wednesday, September 30, 2026, in New York City. Rogers’ President and CEO Ali El-Haj and other members of the senior leadership team will provide details on Rogers’ strategy, key growth opportunities, capital allocation priorities and multi-year financial objectives. The event will include formal presentations from Rogers’ management team, followed by a question-and
SpaceX’s Starlink in Focus as FCC Moves to Expand Satellite Broadband Spectrum; To Vote on Sept. 30
FCC will vote on unlocking 1,000+ MHz of spectrum, potentially boosting Starlink capacity and satellite broadband competition.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-05 | Russell Laura | -31 | $127.82 | $3,962 |
| 2026-08-14 | Reeder Raymond Sean | -15 | $142.91 | $2,144 |
| 2026-07-12 | El-Haj Ali Omar | -8,918 | $137.52 | $1,226,403 |
| 2026-05-19 | El-Haj Ali Omar | +24,822 | - | - |
| 2026-05-06 | Moh Woon Keat | +1,427 | - | - |
| 2026-05-06 | Lauzon Armand F Jr | +1,427 | - | - |
| 2026-05-06 | Faust Megan | +1,427 | - | - |
| 2026-05-06 | COPE BRETT ALAN | +1,427 | - | - |
| 2026-05-06 | Roby Anne K | +1,427 | - | - |
| 2026-05-06 | Starkloff Eric Howard | +1,427 | - | - |
| 2026-05-06 | Berger Larry L | +1,427 | - | - |
| 2026-05-06 | Costello Donna | +1,427 | - | - |
| 2026-05-06 | OWENS JEFFREY J | +1,427 | - | - |
| 2026-05-01 | Larabee Brian Keith | -830 | $135.91 | $112,805 |
| 2026-04-30 | Wallace Peter C | -1,430 | $132.633 | $189,665 |
| 2026-04-30 | Wallace Peter C | -967 | $131.5609 | $127,219 |
| 2026-03-11 | Morton Jessica Ann | -248 | $105.01 | $26,042 |
| 2026-03-02 | Webb Michael Reed | -954 | $111.311 | $106,191 |
| 2026-02-28 | Russell Laura | -456 | $107.83 | $49,170 |
| 2026-02-28 | Reeder Raymond Sean | -69 | $107.83 | $7,440 |
| 2026-02-28 | Webb Michael Reed | -351 | $107.83 | $37,848 |
| 2026-02-28 | Morton Jessica Ann | -427 | $107.83 | $46,043 |
| 2026-02-28 | Larabee Brian Keith | -232 | $107.83 | $25,017 |
| 2026-02-28 | Tsao Jeff | -257 | $107.83 | $27,712 |
| 2026-02-21 | Tsao Jeff | -181 | $107.49 | $19,456 |
| 2026-02-20 | Webb Michael Reed | -673 | $107.2844 | $72,202 |
| 2026-02-19 | Webb Michael Reed | -1,197 | $106.25 | $127,181 |
| 2026-02-19 | Webb Michael Reed | -307 | $111.11 | $34,111 |
| 2026-02-19 | Morton Jessica Ann | -374 | $111.11 | $41,555 |
| 2026-02-19 | Larabee Brian Keith | -173 | $111.11 | $19,222 |
| 2026-02-19 | Tsao Jeff | -162 | $111.11 | $18,000 |
| 2026-02-19 | Wallace Peter C | -8,000 | $107.3684 | $858,947 |
| 2026-02-18 | Webb Michael Reed | +3,451 | - | - |
| 2026-02-18 | Russell Laura | +5,002 | - | - |
| 2026-02-18 | Morton Jessica Ann | +3,451 | - | - |
| 2026-02-18 | Larabee Brian Keith | +2,502 | - | - |
| 2026-02-18 | Tsao Jeff | +3,451 | - | - |
| 2026-02-13 | Reeder Raymond Sean | -53 | $107.79 | $5,713 |
| 2026-02-13 | Russell Laura | -58 | $107.79 | $6,252 |
| 2026-02-12 | Reeder Raymond Sean | +651 | - | - |
| 2026-02-09 | Larabee Brian Keith | -281 | $106.1 | $29,814 |
| 2025-12-10 | Russell Laura | -257 | $91.7 | $23,567 |
| 2025-11-11 | Wallace Peter C | -3,590 | $85.0012 | $305,154 |
| 2025-11-10 | Wallace Peter C | -110 | $86 | $9,460 |
| 2025-10-31 | Larabee Brian Keith | -775 | $85.8658 | $66,546 |